Dermatology specialist Galderma (SWX:GALD) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Restylane Lyft with Lidocaine, expanding its use to include chin augmentation for adults with mild-to-moderate chin retrusion.

This makes Restylane Lyft the only hyaluronic acid injectable approved in the United States to treat the midface, facial folds and wrinkles, back of hands and the chin.

The approval follows a pivotal clinical trial demonstrating significant and sustained improvement in chin projection, with 99% of investigators and 95% of patients reporting visible enhancement at three months, and high satisfaction maintained through 12 months. The study confirmed both safety and long-term efficacy, with no serious product-related adverse events.

Developed with Galderma's proprietary NASHA technology, Restylane Lyft features a firmer gel structure designed to provide balance and definition to the lower face. Supported by more than 20 years of safety data and over 77 million Restylane treatments worldwide, this milestone reinforces Galderma's leadership in aesthetic dermatology.

Regulatory submissions for the new chin indication are underway in additional markets.